Oxford/AstraZeneca (AZN) vaccine data looks 'mediocre' - STAT's Feuerstein

Oxford/AstraZeneca (NYSE: AZN) vaccine data looks "mediocre", STAT's Adam Feuerstein said on Twitter.

I am NOT a vaccine expert but the Oxford $AZN data look mediocre to me — disappointing relative to all the hype coming into Monday.

Is this how others more knowledgable than me see it, too?

What am I missing here?

— Adam Feuerstein (@adamfeuerstein) July 20, 2020

You May Also Be Interested In

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
• Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
• DOJ, TikTok settle for $400m in children's privacy suit - Axios